HK1069771A1 - Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis - Google Patents

Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis

Info

Publication number
HK1069771A1
HK1069771A1 HK05102272.0A HK05102272A HK1069771A1 HK 1069771 A1 HK1069771 A1 HK 1069771A1 HK 05102272 A HK05102272 A HK 05102272A HK 1069771 A1 HK1069771 A1 HK 1069771A1
Authority
HK
Hong Kong
Prior art keywords
phenoxy
osteoporosis
thiazolyl
alkoxy
treatment
Prior art date
Application number
HK05102272.0A
Other languages
English (en)
Inventor
Hong-Suk Suh
Jin-Soo Lee
Pan-Soo Kim
Yun-Ha Hwang
Jei-Man Ryu
Yong-Ho Chung
Eun-Joo Kim
Do-Hui Kim
Yong-Youp Park
Original Assignee
Dong Wha Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Ind Co Ltd filed Critical Dong Wha Pharm Ind Co Ltd
Publication of HK1069771A1 publication Critical patent/HK1069771A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK05102272.0A 2001-07-19 2005-03-15 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis HK1069771A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2001-0043490A KR100454767B1 (ko) 2001-07-19 2001-07-19 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
PCT/KR2002/000463 WO2003007947A1 (en) 2001-07-19 2002-03-19 Use of 4-[(4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis

Publications (1)

Publication Number Publication Date
HK1069771A1 true HK1069771A1 (en) 2005-06-03

Family

ID=19712300

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102272.0A HK1069771A1 (en) 2001-07-19 2005-03-15 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis

Country Status (14)

Country Link
US (2) US7662840B2 (xx)
EP (1) EP1411935B1 (xx)
JP (1) JP4047275B2 (xx)
KR (1) KR100454767B1 (xx)
CN (1) CN100435794C (xx)
AT (1) ATE468117T1 (xx)
AU (1) AU2002241361B2 (xx)
BR (1) BR0211329A (xx)
CA (1) CA2454022C (xx)
DE (1) DE60236438D1 (xx)
ES (1) ES2342155T3 (xx)
HK (1) HK1069771A1 (xx)
WO (1) WO2003007947A1 (xx)
ZA (1) ZA200400331B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242152B2 (en) 2001-07-19 2012-08-14 Dong Wha Pharmaceutical Co., Ltd. Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for the prophylaxis and treatment of osteoporosis
KR100454767B1 (ko) 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
EP1773794A4 (en) * 2004-07-05 2009-09-09 Dong Wha Pharm Ind Co Ltd IMPROVED METHOD FOR PREPARING N-HYDROXY-4 {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) -PHENOXY] -PENTOXY} -BENZAMIDINE
CA2572897C (en) * 2004-07-05 2010-08-24 Dong Wha Pharmaceutical Ind. Co., Ltd. Pharmaceutical composition for the treatment of bone fracture
JP4657297B2 (ja) * 2004-07-05 2011-03-23 ドン ファ ファーマシューティカル カンパニー リミテッド アレルギー性炎症疾患の予防及び治療用組成物
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
EP1701722B1 (en) * 2004-11-23 2009-10-14 Dong Wha Pharmaceutical Co., Ltd. N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy¨]pentoxy}benzamidine 2 methansulfonic acid salt
CN101351707B (zh) * 2005-12-28 2014-03-26 积水医疗株式会社 凝集测量用试剂以及凝集测量方法
WO2007089101A1 (en) 2006-01-31 2007-08-09 Dong Wha Pharmaceutical Ind.Co., Ltd. Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
EP2146974B1 (en) * 2007-04-19 2011-01-05 Dong Wha Pharmaceutical Co., Ltd. N- hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same
AU2008283211B2 (en) * 2007-07-27 2011-04-07 Dong Wha Pharmaceutical Co., Ltd. Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same
CA2694638A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
US7964584B2 (en) 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
EP2307015A4 (en) * 2008-08-01 2012-05-16 Dong Wha Pharm Co Ltd PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS BASED ON DERIVATIVES OF BENZAMIDINE OR SALTS THEREOF, AND ALENDRONIC ACID OR SALTS THEREOF
WO2010087517A1 (ja) 2009-01-30 2010-08-05 帝人ファーマ株式会社 骨代謝異常に起因する疾患の予防剤又は治療剤
EP3383868B1 (en) 2015-11-30 2022-10-05 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
EP3383388B1 (en) 2015-11-30 2021-04-14 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
JP7373191B2 (ja) 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスa gpcr結合性化合物改変体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488160A (en) * 1991-06-11 1996-01-30 Ciba-Geigy Corporation Amidino compounds, their manufacture and method of treatment
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
CN1244196A (zh) 1997-02-04 2000-02-09 同和药品工业株式会社 3-氨基-1,2-苯并异噁唑衍生物,其制备方法和应用
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
KR100454767B1 (ko) 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도

Also Published As

Publication number Publication date
JP2004537549A (ja) 2004-12-16
CA2454022C (en) 2009-10-13
DE60236438D1 (de) 2010-07-01
EP1411935A4 (en) 2005-11-09
JP4047275B2 (ja) 2008-02-13
ZA200400331B (en) 2005-06-29
US20100120875A1 (en) 2010-05-13
CN1533275A (zh) 2004-09-29
BR0211329A (pt) 2004-09-28
KR100454767B1 (ko) 2004-11-03
US7662840B2 (en) 2010-02-16
CN100435794C (zh) 2008-11-26
US8227496B2 (en) 2012-07-24
US20040186150A1 (en) 2004-09-23
KR20030008654A (ko) 2003-01-29
ATE468117T1 (de) 2010-06-15
EP1411935A1 (en) 2004-04-28
CA2454022A1 (en) 2003-01-30
AU2002241361B2 (en) 2007-01-25
WO2003007947A1 (en) 2003-01-30
EP1411935B1 (en) 2010-05-19
ES2342155T3 (es) 2010-07-02

Similar Documents

Publication Publication Date Title
HK1069771A1 (en) Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis
TW200420549A (en) Thiazole derivatives
WO2006011631A3 (en) Thiazole derivatives having vap-1 inhibitory activity
KR940019699A (ko) 옥사졸리딘디온 유도체, 그의 제조방법 및 용도
SG156517A1 (en) Methods and compositions for treating hepatitis c virus
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
MXPA02011641A (es) Metodos para tatar infecciones por viurs de hepatitis delta con beta-l-2'-desoxi-nucleosidos.
AU2483000A (en) Treatment of asthma with mek inhibitors
BG106287A (en) Respiratory syncytial virus replication inhibitors
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
MY150903A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
GB0024361D0 (en) Medicaments
AP1441A (en) Hydrate of 5- [4-{2-(N-methlyl-N-(2-pyridil) amino) ethoxy} benzyl] thiazolidine-2,4-dione maleic acid salt.
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
CA2572897A1 (en) Pharmaceutical composition for the treatment of bone fracture
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
HUP0202836A2 (hu) Piridazinonszármazék új alkalmazása
RU96120159A (ru) Производные тиазолидиндиона в качестве противогипергликемических средств
MXPA04003631A (es) Rosuvastatina en estados de pre-demencia.
KR970701704A (ko) 항과혈당제로서의 티아졸리딘디온 유도체(Thiazolidinedione derivatives as antihyperglycemic agents)
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
NZ337927A (en) Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (NIDDM) using specific retinoid compounds
EP2146974A4 (en) SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT
AP2002002673A0 (en) Thiazolidinedione salt for the treatment of diabetes mellitus.
WO2007146039A3 (en) Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220318